Health Canada–approved direct-acting antiviral regimens in Canada
| Regimen | Genotype | Pills per day | Duration (wk) | Comments |
|---|---|---|---|---|
| Genotype-specific treatment regimens | ||||
| Elbasvir/grazoprevir (Zepatier) | 1a, 1b, 4 | 1 | 12–16 | Resistance testing recommended before use in genotype 1a |
| Ledipasvir/sofosbuvir (Harvoni) | 1a, 1b, 4, 5, 6 | 1 | 8–24 | |
| Paritaprevir/ritonavir/ombitasvir + dasabuvir (Holkira Pak) | 1, 1b | 4 | 8–24 | Ribavirin must be added for genotype 1a |
| Paritaprevir/ritonavir/ombitasvir (Technivie) | 4 | 2 | 12 | Ribavirin must be added |
| Sofosbuvir + daclatasvir (Sovaldi + Daklinza) | 1a, 1b, 3 | 2 | 12–24 | |
| Pan-genotypic regimens | ||||
| Glecaprevir/pibrentasvir (Maviret) | 1–6 | 3 | 8–16 | |
| Sofosbuvir/velpatasvir (Epclusa) | 1–6 | 1 | 12 | |
| Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) | 1–6 | 1 | 12 | Approved only for direct-acting antiviral agent failures |